XML 73 R47.htm IDEA: XBRL DOCUMENT v3.24.0.1
SEGMENT INFORMATION (Tables)
12 Months Ended
Dec. 31, 2023
Segment Reporting [Abstract]  
Schedule of Information About Reportable Segments and Reconciliation of Segment Net Sales and Pre-Tax Income
The table below presents information about Edwards Lifesciences' reportable segments (in millions):
 Years Ended December 31,
 202320222021
Segment Net Sales   
United States$3,508.7 $3,132.6 $2,963.1 
Europe1,337.4 1,213.7 1,099.6 
Japan436.7 559.3 528.0 
Rest of World716.9 610.7 533.2 
Total segment net sales$5,999.7 $5,516.3 $5,123.9 
Segment Operating Income  
United States$2,306.1 $2,130.9 $2,051.0 
Europe709.5 652.2 569.1 
Japan259.1 376.7 348.0 
Rest of World310.4 247.7 185.2 
Total segment operating income$3,585.1 $3,407.5 $3,153.3 

The table below presents reconciliations of segment net sales to consolidated net sales and segment operating income to consolidated pre-tax income (in millions):
 Years Ended December 31,
 202320222021
Net Sales Reconciliation   
Segment net sales$5,999.7 $5,516.3 $5,123.9 
Foreign currency5.1 (133.9)108.6 
Consolidated net sales$6,004.8 $5,382.4 $5,232.5 
Pre-tax Income Reconciliation  
Segment operating income$3,585.1 $3,407.5 $3,153.3 
Unallocated amounts:
Corporate items(1,920.9)(1,714.1)(1,613.8)
Special charge and separation costs(17.2)(60.7)— 
Intellectual property agreement and litigation expense(203.5)(15.8)(20.6)
Change in fair value of contingent consideration liabilities26.2 35.8 124.1 
Foreign currency64.4 95.8 47.3 
Consolidated operating income1,534.1 1,748.5 1,690.3 
Non-operating income64.0 18.9 11.7 
Consolidated pre-tax income$1,598.1 $1,767.4 $1,702.0 
Schedule of Enterprise-Wide Information
Enterprise-wide information is based on actual foreign exchange rates used in the Company's consolidated financial statements.

 As of or for the Years Ended December 31,
 202320222021
Net Sales by Geographic Region   
United States$3,508.7 $3,132.6 $2,963.1 
Europe1,334.5 1,174.8 1,190.3 
Japan452.4 473.6 528.9 
Rest of World709.2 601.4 550.2 
$6,004.8 $5,382.4 $5,232.5 
Net Sales by Major Product Group  
Transcatheter Aortic Valve Replacement$3,879.8 $3,518.2 $3,422.5 
Transcatheter Mitral and Tricuspid Therapies197.6 116.1 86.0 
Surgical Structural Heart999.3 893.1 889.1 
Critical Care928.1 855.0 834.9 
$6,004.8 $5,382.4 $5,232.5 
Long-lived Tangible Assets by Geographic Region   
United States$1,269.7 $1,188.5 $1,195.8 
Europe196.4191.8197.9
Japan23.813.219.7
Rest of World353.5331.6335.5
$1,843.4 $1,725.1 $1,748.9